Trending
Revolutionary Shows Promise 4
Revolutionary Shows Promise 3
Revolutionary Shows Promise 1
Revolutionary aids Treatment Shows Promise
Revolutionary Cancer Treatment Shows Promise
FDA Expands Approval of Vonvendi for von Willebrand Disease, Including Pediatric Use
Child Depression Fluctuations may trigger Parent Depression not vice versa: JAMA
Indoor Air Quality and Diet Found to Regulate Inflammation in Childhood: Study Finds
How Smoking Fuels Pancreatic Cancer Growth and Worsens Outcomes: Study Finds Out
Follow Us:
November 02, 2025

Get In Touch

Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide Pharma News

Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide

  • 25 October 2025
  • 1 week ago

Study confirms cardiovascular benefits of semaglutide beyond weight loss: LANCET Diabetes and Endocrinology

Study confirms cardiovascular benefits of semaglutide beyond weight loss: LANCET

  • 25 October 2025
  • 1 week ago

FDA Approves Oral Semaglutide for Cardiovascular Risk Reduction in Type 2 Diabetes Diabetes and Endocrinology

FDA Approves Oral Semaglutide for Cardiovascular Risk Reduction in Type 2 Diabetes

  • 23 October 2025
  • 1 week ago

CDSCO Panel Seeks More Toxicity Data from Macleods on Semaglutide Injection Pre-Filled Pens Pharma News

CDSCO Panel Seeks More Toxicity Data from Macleods on Semaglutide Injection Pre-Filled Pens

  • 23 October 2025
  • 1 week ago

Biocon Told to Submit Detailed Toxicity, SAE Data on Semaglutide Prefilled Pen After Animal Deaths Pharma News

Biocon Told to Submit Detailed Toxicity, SAE Data on Semaglutide Prefilled Pen After Animal Deaths

  • 21 October 2025
  • 1 week ago

Comparable Cardiorenal Outcomes Among Three GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes: JAMA Diabetes and Endocrinology

Comparable Cardiorenal Outcomes Among Three GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes: JAMA

  • 18 October 2025
  • 2 weeks ago

Alkem Labs Gets CDSCO Panel Nod for conducting Phase III study of Semaglutide tablet Pharma News

Alkem Labs Gets CDSCO Panel Nod for conducting Phase III study of Semaglutide tablet

  • 14 October 2025
  • 2 weeks ago

CDSCO Panel seeks clarifications from Novo Nordisk on IcoSema phase IIIb clinical study protocol Pharma News

CDSCO Panel seeks clarifications from Novo Nordisk on IcoSema phase IIIb clinical study protocol

  • 11 October 2025
  • 3 weeks ago

Once-Weekly Semaglutide bests Sitagliptin for blood sugar, Weight, and Lipid Profile control in T2DM: Study Diabetes and Endocrinology

Once-Weekly Semaglutide bests Sitagliptin for blood sugar, Weight, and Lipid Profile control in T2DM: Study

  • 25 September 2025
  • 1 month ago

Taking semaglutide turns down food noise, research suggests Diabetes and Endocrinology

Taking semaglutide turns down food noise, research suggests

  • 23 September 2025
  • 1 month ago

Recent News

Delhi Govt to recruit 1,593 senior resident doctor...

  • 02 November, 2025

Former Drug Inspector's Office Clerk Jailed for Ta...

  • 02 November, 2025

Emcure Pharma Gets CDSCO Panel Nod to Conduct Phas...

  • 02 November, 2025

MSN Labs Secures SEC Nod for Phase III Trial of Vi...

  • 02 November, 2025

Daily Newsletter

Get all the top stories from Blogs to keep track.